DOCSLIB.ORG

Formulary (List of Covered Drugs)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Formulary (List of Covered Drugs) Plan Year 2021 2021 Formulary (List of Covered Drugs) PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN THE FOLLOWING PLAN: $0 Cost Share AI/AN HMO Minimum Coverage HMO Silver 70 HMO Active Choice PPO Silver Opal 25 Gold HMO Silver 70 OFF Exchange HMO Amber 50 HMO Silver Opal 50 Silver HMO Silver 73 HMO Bronze 60 HDHP HMO Platinum 90 HMO Silver 87 HMO Bronze 60 HMO Ruby 10 Platinum HMO Silver 94 HMO Gold 80 HMO Ruby 20 Platinum HMO Jade 15 HMO Ruby 40 Platinum HMO This formulary was last updated on 4//201. This formulary is subject to change and all previous versions of the formulary no longer apply. For more recent information or other questions, please contact Chinese Community Health Plan Member Services at 1-888-775-7888 or, for TTY users, 1-877-681-8898, seven days a week from 8:00 a.m. to 8:00 p.m., or visit www.cchphealthplan.com/family-member -,-1 -,-1"&* !#" + 5 5 ),-$+" %(%'.')/"+#" %&/"+ -%/"$)% "%&/"+ *& )&! %&/"+ 0 $(#" '"+ %&/"+ *& %&/"+ %&/"+ +)(2" &-%(.' %&/"+ +)(2" .1&-%(.' %&/"+ )&! .1&-%(.' !" .1&-%(.' This formulary was last updated 4/1/2021. This formulary is subject to change and all previous versions of the formulary no longer apply. For more recent information or other questions, please contact Chinese Community Health Plan Member Services at 1-888-775-7888 or, for TTY users, 1-877-681-8898, seven days a week from 8:00 a.m. to 8:00 p.m., or visit www.cchphealthplan.com/family-member !! %+)&,+ &%+&+&)$,#)0),# *+666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666I % + &%*6666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666I &.& %),&%+ *# *+26666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666J &.& "%&. +),# *+ *)%&)%) ),26666666666666666666666666666666666666666666666666666666666666666J +)),+ )*26666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666K &.+&)+&)$,#)0666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666K &.&+%. ##+&)$,#)0%26666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666L + *$ #% +),-)*,*),&-),%)+,+'+ %+)*) '+ &%),% +2 666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666L +)')-%+ -#+),*2666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666L + *&%+)'+ -),&)- 26666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666M + +*)),*%')&,+*)&-),%)+,+'+ %+)*) '+ &%),% +2M + 0&,)), *&-),%)+$ #% +2666666666666666666666666666666666666666666666666666666666666666666666M + **+'+)'0266666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666M + *+') &),+&) 1+ &%:/'+ &%)(,*+')&**26666666666666666666666666666666666666666666666666666666666666666M )+ '+ %)+ #')$ *666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666N +)*' #+0),*26666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666N #&))')$0666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666N + 0&,)), *%&+&%+&)$,#)02666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666N H !"!!!"&" ! ),&)$,#)0 *# *+&$ + &%*++)'')&-0+&&%),$ % *+)+ &% =>%)*#+*&%*+03+ -%**3%&*+6 *# *+&%) %)%),* * &-)00&,)#+ %*,)%'&# 0,%)+')*) '+ &%),% +&+'&# 06 ! &##&. %.&)*% % + &%*. ##,*+)&,&,++&)$,#)0),# *+6 )%%$), ),++ *$)"+,%)')&') +)03+)$)"')&++%$6 )%%$),*### *+ %## #++)*6 & %*,)% ')%+&+&*+&&-)#+)% +++%%)&## '0*+)+%)&##*' +,+ #3 ,+ #''# *+&+ #+)% +3*,*+')*) '+ &%),% +6 &'0$%+ /&##)$&,%+++%%)&##'0*&)&-)#+)% + +)+%)&##*' +,+ #3 ,+ #''# *+&+ #+)% +3*,*+')*) '+ &%),% +6 ,+ # $&,%+%%)&##'0*&)&-)#+)% +*&)+ %)&##@*#+'#% %*'0$%+&)##&)')+&+&*+&+#+ )% +,%)++)$*&+'&# 06 ),+ ) )&,'&')*) '+ &%),*++&))*'&%*+&*' &*+*) % + ) %+#+'#%@*')*) '+ &%),&-)6+ ) %. ')*) '+ &%), *'#+)$ %*+%)&##@*'&)+ &%&+&*+&) +),6 %)&## ')*&%%)&## %#+'#%.& *%+ +#+&) -*)- *)&$ +'#%6##))%*+&%)&##* %+ *+ *&)$,#)0+$'#+*###*& %#,*,*) )* % %+ **+ &%#&.6 /'+ &%)(,*+ )(,*+&)&-)&')*) '+ &%),6 %%)&##3 *&)) * %3&)')*) %#+)')&- )*,$ +*%/'+ &%)(,*+ &)&-)&')*) '+ &%),3+#+'#%$,*+&-)+ ')*) '+ &%),.%+), *+)$ %+&$ ##0%**)0+& +)++%)&##@*&% + &%6 / %+ ),$*+%* ).%%%)&## **,) %)&$#+&% + &%++$0*) &,*#0 !&') 1+%)&##@*# 3#+3&) # +0+&) %$/ $,$,%+ &%3 &).%%%)&## *,%)& %,))%+&,)*&+)+$%+,* % %&%;&)$,#)0),6 &)$,#)0 &$'#+# *+&),*')))&),*%# #&)&-),%) #+'#%')&,+3% %#,*##),*&-),%)+&,+'+ %+ ')*) '+ &%),% +&+#+'#%')&,+6&)$,#)0 *#*& "%&.%*')*) '+ &%),# *+6 %) ), *$),* +*)%%$(, -#%+ %&*3*+03*+)%+3&. + *+"%3(,# +03')&)$%3% %+%,*6%) ), *# *+ % &#% +# 1#&.)*#++)*6 &%;&)$,#)0), ')*) '+ &%),++ *%&+# *+&%+#+'#%@*&)$,#)06 ,+;&;'&"+&*+* )&'0$%+*3& %*,)%3%+''# #,+ #3'#,*##&*+* &)#+)*)- *++)%&+&-)0+#+'#%6 I )*) %')&- ) #+)')&- ),+&) 1+&.) +')*) '+ &%+&+)+$ # &% + &%&)#+'#%%)&##6 )*) '+ &% %&)#3.) ++%3&)#+)&% &))0')*) %')&- )&)*' %)&##++&%+ %*+%$&+')*) '+ &%),3+(,%+ +0&+ ')*) ),3++& **,3+%$%&%++ %&)$+ &%&+ ')*) %')&- )3+* %+,)&+')*) %')&- ) + ')*) '+ &% * %.) + %3% )(,*+0+%)&##3+$ # &% + &%&)',)'&*&). +), * %')*) 6 )*) '+ &%), ),++ *')*) 0+%)&##7*')*) %')&- )%)(, )* ')*) '+ &%,%)''# ##.6 ) &),+&) 1+ &% #+'#%@*)(, )$%++++%)&##&)+%)&##@*')*) % ')&- )&+ %+#+'#%@*,+&) 1+ &%&)')*) '+ &%),&) +#+'#%. ##&-)+),6#+'#%*##)%+') &) ,+&) 1+ &%.% + *$ ##0%**)0&)+%)&##+&&+ %+ ),6 ,%+ +0# $ + *+) + &%&%+%,$)&&**&)%0&+)# $ ++ &%*&%+(,%+ +0 &')*) '+ &%),#+'#%. ##&-),) %*' + $') &6 +'+)'0 ')&***' 0 %+*(,% %. )%+')*) '+ &%),*&) -%$ #&% + &%%$ ##0'')&') +&)')+ ,#)'+ %+ )')*) 6#+'#%$0)(, )+%)&##+&+)0&%&)$&) ),*+&+)++%)&##@*$ #&% + &%&)+#+'#%. ## &-)')+ ,#)),&)+&% + &%',)*,%++&*+'+)'0)(,*+6 +%)&##@*')*) %')&- )*,$ +*)(,*+&)*+'+)'0 /'+ &%3+#+'#%**##$"/'+ &%*+&*+'+)'0.%+ ) +) *$+6 ,*) ) ')*&%.& *)*'&%* #&)'0$%++&'#%&).&*$'#&0$%+ &)&+)*++,*3/'+ &%&)$ #0'%%03 *+* *&)# # +0 &)$$)* ' %+'#%6 $"! !( ),*)# *+#'+ ##0,%)+&#,$%+ +#8)*) '+ &%), $90 +*)%&) %) %$,%)++)',+ +&)0%#**+&. +#&%*6&,%*)+ *# *+,* % +)%&)%) %$&+),05 < ) %&)++&)0&)#**+&. +),#&%*%*)&)+%$&+), % #'+ #&))&) < ) %+#'+ # %/&),*0+%$&+),6 %) (, -#%+&))%%$), *%&+- ##&) *%&+&-)3+),. ##%&+ *')+#0# *+0 +*%) %$6 *+ %),&%+&)$,#)0&*%&+,)%+++ +. ##')*) 00&,)&+&)&) ')*) )6 $$!" ! "( < %) %$),&))%%$), *# *+ %###&.)*&# +# * J < )%%$), *# *+ %## o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rugs, Drugs, e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
Load more

Recommended publications
  • GABA Receptors
    D Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews Review No.7 / 1-2011 GABA receptors Wolfgang Froestl , CNS & Chemistry Expert, AC Immune SA, PSE Building B - EPFL, CH-1015 Lausanne, Phone: +41 21 693 91 43, FAX: +41 21 693 91 20, E-mail: [email protected] GABA Activation of the GABA A receptor leads to an influx of chloride GABA ( -aminobutyric acid; Figure 1) is the most important and ions and to a hyperpolarization of the membrane. 16 subunits with γ most abundant inhibitory neurotransmitter in the mammalian molecular weights between 50 and 65 kD have been identified brain 1,2 , where it was first discovered in 1950 3-5 . It is a small achiral so far, 6 subunits, 3 subunits, 3 subunits, and the , , α β γ δ ε θ molecule with molecular weight of 103 g/mol and high water solu - and subunits 8,9 . π bility. At 25°C one gram of water can dissolve 1.3 grams of GABA. 2 Such a hydrophilic molecule (log P = -2.13, PSA = 63.3 Å ) cannot In the meantime all GABA A receptor binding sites have been eluci - cross the blood brain barrier. It is produced in the brain by decarb- dated in great detail. The GABA site is located at the interface oxylation of L-glutamic acid by the enzyme glutamic acid decarb- between and subunits. Benzodiazepines interact with subunit α β oxylase (GAD, EC 4.1.1.15). It is a neutral amino acid with pK = combinations ( ) ( ) , which is the most abundant combi - 1 α1 2 β2 2 γ2 4.23 and pK = 10.43.
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Formulary (List of Covered Drugs)
    3ODQ<HDU 202 Formulary (List of Covered Drugs) PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN THE FOLLOWING PLAN: $0 Cost Share AI/AN HMO Minimum Coverage HMO Silver 70 HMO Active Choice PPO Silver Opal 25 Gold HMO Silver 70 OFF Exchange HMO Amber 50 HMO Silver Opal 50 Silver HMO Silver 73 HMO Bronze 60 HDHP HMO Platinum 90 HMO Silver 87 HMO Bronze 60 HMO Ruby 10 Platinum HMO Silver 94 HMO Gold 80 HMO Ruby 20 Platinum HMO Jade 15 HMO Ruby 40 Platinum HMO This formulary was last updated on8//20. This formulary is VXEMHFWto change and all previous versions of the formulary no longer apply. For more recent information or other questions, please contact Chinese Community Health Plan Member Services at 1-888-775-7888 or, for TTY users, 1-877-681-8898, seven days a week from 8:00 a.m. to 8:00 p.m., or visit www.cchphealthplan.com/family-member -,-ϭ -,-ϭ"&* !#" + 5 5 ),-$+" %(%'.')/"+#" %&/"+ -%/"$)% "%&/"+ *& )&! %&/"+ 0 $(#" '"+ %&/"+ *& %&/"+ %&/"+ +)(2" &-%(.' %&/"+ +)(2" .1&-%(.' %&/"+ )&! .1&-%(.' !" .1&-%(.' dŚŝƐĨŽƌŵƵůĂƌLJǁĂƐůĂƐƚƵƉĚĂƚĞĚ8ͬϭͬϮϬϮϭ͘dŚŝƐĨŽƌŵƵůĂƌLJŝƐƐƵďũĞĐƚƚŽ ĐŚĂŶŐĞĂŶĚĂůůƉƌĞǀŝŽƵƐǀĞƌƐŝŽŶƐŽĨƚŚĞĨŽƌŵƵůĂƌLJŶŽůŽŶŐĞƌĂƉƉůLJ͘&ŽƌŵŽƌĞ ƌĞĐĞŶƚŝŶĨŽƌŵĂƚŝŽŶŽƌŽƚŚĞƌƋƵĞƐƚŝŽŶƐ͕ƉůĞĂƐĞĐŽŶƚĂĐƚŚŝŶĞƐĞŽŵŵƵŶŝƚLJ ,ĞĂůƚŚWůĂŶDĞŵďĞƌ^ĞƌǀŝĐĞƐĂƚϭͲϴϴϴͲϳϳϱͲϳϴϴϴŽƌ͕ĨŽƌddzƵƐĞƌƐ͕ ϭͲϴϳϳͲϲϴϭͲϴϴϵϴ͕ƐĞǀĞŶĚĂLJƐĂǁĞĞŬĨƌŽŵϴ͗ϬϬĂ͘ŵ͘ƚŽϴ͗ϬϬƉ͘ŵ͕͘ŽƌǀŝƐŝƚ ǁǁǁ͘ĐĐŚƉŚĞĂůƚŚƉůĂŶ͘ĐŽŵͬĨĂŵŝůLJͲŵĞŵďĞƌ !! %+)&,+ &%+&+&)$,#)0),# *+666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666I % + &%*6666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666I
    [Show full text]
  • No Evidence of Altered in Vivobenzodiazepine Receptor Binding in Schizophrenia
    No Evidence of Altered In Vivo Benzodiazepine Receptor Binding in Schizophrenia Anissa Abi-Dargham, M.D., Marc Laruelle, M.D., John Krystal, M.D., Cyril D’Souza, M.D., Sami Zoghbi, Ph.D., Ronald M. Baldwin, Ph.D., John Seibyl, M.D., Osama Mawlawi, Ph.D., Gabriel de Erasquin, M.D., Ph.D., Dennis Charney, M.D., and Robert B. Innis, M.D., Ph.D. Deficits in gamma-amino-butyric acid (GABA) of this measurement was established in four healthy neurotransmitter systems have been implicated in the volunteers. No differences in regional BDZ VT were pathophysiology of schizophrenia for more than two observed between 16 male schizophrenic patients and 16 decades. Previous postmortem and in vivo studies of matched controls. No relationships were observed between benzodiazepine (BDZ) receptor density have reported BDZ VT and severity of psychotic symptoms in any of the alterations in several brain regions of schizophrenic regions examined. In conclusion, this study failed to patients. The goal of this study was to better characterize identify alterations of BDZ receptors density in possible alterations of the in vivo regional distribution schizophrenia. If this illness is associated with deficits in volume (VT) of BDZ receptors in schizophrenia, using the GABA transmission, these deficits do not substantially selective BDZ antagonist [123I]iomazenil and single photon involve BDZ receptor expression or regulation. emission computerized tomography (SPECT). Regional [Neuropsychopharmacology 20:650-661, 1999] BDZ VT was measured under sustained radiotracer © 1999 American College of Neuropsychopharmacology. equilibrium conditions. The reproducibility and reliability Published by Elsevier Science Inc. KEY WORDS: Schizophrenia; Benzodiazepine receptors; that disinhibition of dopamine function in schizophre- [123I]iomazenil; SPECT nia may stem from a deficit in inhibitory, GABA medi- ated systems (Roberts 1972; Stevens 1975; van Kammen Alterations of gamma-amino-butyric acid (GABA) sys- 1977).
    [Show full text]
  • Anthem Blue Cross Prescription Formulary List
    National Drug List Drug list — Three Tier Drug Plan Your prescription benefit comes with a drug list, which is also called a formulary. This list is made up of brand-name and generic prescription drugs approved by the U.S. Food & Drug Administration (FDA). We’re here to help. If you are a current Anthem member with questions about your pharmacy benefits, we're here to help. Just call us at the Member Services number on your ID card. The plan names to which this formulary applies are shown below. Solution PPO 1500/15/20 $5/$15/$50/$65/30% to $250 after deductible Solution PPO 2000/20/20 $5/$20/$30/$50/30% to $250 Solution PPO 2500/25/20 $5/$20/$40/$60/30% to $250 Solution PPO 3500/30/30 $5/$20/$40/$60/30% to $250 Rx ded $150 Solution PPO 4500/30/30 $5/$20/$40/$75/30% to $250 Solution PPO 5500/30/30 $5/$20/$40/$75/30% to $250 Rx ded $250 $5/$15/$25/$45/30% to $250 $5/$20/$50/$65/30% to $250 Rx ded $500 $5/$15/$30/$50/30% to $250 $5/$20/$50/$70/30% to $250 $5/$15/$40/$60/30% to $250 $5/$20/$50/$70/30% to $250 after deductible Here are a few things to remember: o You can view and search our current drug lists when you visit anthem.com/ca/pharmacyinformation. Please note: The formulary is subject to change and all previous versions of the formulary are no longer in effect.
    [Show full text]
  • Transporters
    Alexander, S. P. H., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., Sharman, J. L., Southan, C., Davies, J. A., & CGTP Collaborators (2019). The Concise Guide to Pharmacology 2019/20: Transporters. British Journal of Pharmacology, 176(S1), S397-S493. https://doi.org/10.1111/bph.14753 Publisher's PDF, also known as Version of record License (if available): CC BY Link to published version (if available): 10.1111/bph.14753 Link to publication record in Explore Bristol Research PDF-document This is the final published version of the article (version of record). It first appeared online via Wiley at https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bph.14753. Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/ S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: Transporters. British Journal of Pharmacology (2019) 176, S397–S493 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Transporters Stephen PH Alexander1 , Eamonn Kelly2, Alistair Mathie3 ,JohnAPeters4 , Emma L Veale3 , Jane F Armstrong5 , Elena Faccenda5 ,SimonDHarding5 ,AdamJPawson5 , Joanna L Sharman5 , Christopher Southan5 , Jamie A Davies5 and CGTP Collaborators 1School of Life Sciences,
    [Show full text]
  • Alcohol and Violence: Neuropeptidergic Modulation of Monoamine Systems
    Ann. N.Y. Acad. Sci. ISSN 0077-8923 ANNALS OF THE NEW YORK ACADEMY OF SCIENCES Issue: Addiction Reviews Alcohol and violence: neuropeptidergic modulation of monoamine systems Klaus A. Miczek,1,2 Joseph F. DeBold,2 Lara S. Hwa,2 Emily L. Newman,2 and Rosa M. M. de Almeida3 1Departments of Pharmacology, Psychiatry, and Neuroscience, Tufts University, Boston, Massachusetts. 2Department of Psychology, Tufts University, Medford, Massachusetts. 3Department of Psychology, LPNeC, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil Address for correspondence: Klaus A. Miczek, Department of Psychology, Tufts University, 530 Boston Ave (Bacon Hall), Medford, MA 02155. [email protected] Neurobiological processes underlying the epidemiologically established link between alcohol and several types of social, aggressive, and violent behavior remain poorly understood. Acute low doses of alcohol, as well as withdrawal from long-term alcohol use, may lead to escalated aggressive behavior in a subset of individuals. An urgent task will be to disentangle the host of interacting genetic and environmental risk factors in individuals who are predisposed to engage in escalated aggressive behavior. The modulation of 5-hydroxytryptamine impulse flow by gamma- aminobutyric acid (GABA) and glutamate, acting via distinct ionotropic and metabotropic receptor subtypes in the dorsal raphe nucleus during alcohol consumption, is of critical significance in the suppression and escalation of aggressive behavior. In anticipation and reaction to aggressive behavior, neuropeptides such as corticotropin- releasing factor, neuropeptide Y, opioid peptides, and vasopressin interact with monoamines, GABA, and glutamate to attenuate and amplify aggressive behavior in alcohol-consuming individuals. These neuromodulators represent novel molecular targets for intervention that await clinical validation.
    [Show full text]
  • Advice Concerning the Addition of Certain Pharmaceutical Products
    U.S. International Trade Commission COMMISSIONERS Daniel R. Pearson, Chairman Shara L. Aranoff, Vice Chairman Jennifer A. Hillman Stephen Koplan Deanna Tanner Okun Charlotte R. Lane Robert A. Rogowsky Director of Operations Karen Laney-Cummings Director of Industries Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Advice Concerning the Addition of Certain Pharmaceutical Products and Chemical Intermediates to the Pharmaceutical Appendix to the Harmonized Tariff Schedule of the United States Investigation No. 332--476 Publication 3883 September 2006 This report was prepared principally by Office of Industries Philip Stone, Project Leader With assistance from Elizabeth R. Nesbitt Primary Reviewers David G. Michels, Office of Tariff Affairs and Trde Agreements, John Benedetto, and Nannette Christ, Office of Economics Administrative Support Brenda F. Carroll Under the direction of Dennis Rapkins, Chief Chemicals and Textiles Division ABSTRACT Under the Pharmaceutical Zero-for-Zero Initiative, which entered into force in 1995, the United States and its major trading partners eliminated tariffs on many pharmaceuticals, their derivatives, and certain chemical intermediates used to make pharmaceuticals. The U.S. list of pharmaceutical products and chemical intermediates eligible for duty-free treatment under the agreement is given in the Pharmaceutical Appendix to the Harmonized Tariff Schedule of the United States. The Pharmaceutical Appendix is periodically updated to provide duty relief for additional such products, including newly developed pharmaceuticals. This report provides advice on the third update to the agreement, in which approximately 1,300 products are proposed to receive duty-free treatment.
    [Show full text]
  • Texas Medication Aides Basic Course Curriculum for Nursing Facilities and Related Institutions
    Texas Medication Aides Basic course curriculum for Nursing Facilities and related institutions Effective Date: January 2017 Texas Health and Human Services Commisson (HHSC) Medication Aide Program, E‐416 P.O. Box 14930, Austin, Texas 78714‐9030 Communicate before you medicate! Helping people make the best of medications REVISED JUNE 2016 | Texas Health and Human Services Commisson (HHSC) HHSC Licensing and Credentialing TEXAS MEDICATION AIDE AND BASIC COURSE CURRICULUM 100‐hour curriculum Acknowledgements We would like to extend a very special thank you to the following people who worked many hours in revising and updating this curriculum. Your cooperation and dedication is appreciated. Darren Christian, R.N., Texas Health and Human Services Commisson, Elizabeth Demps, Texas Health and Human Services Commisson, Katherine Hafner, B.S, R.Ph, Fellow in the American Society of Consultant Pharmacists, Kim Lammons Texas Health and Human Services Commisson, Debi Majo, BSN R.N., TMF Health Quality Institute, Elizabeth McManamy, R.Ph, Texas Health and Human Services Commisson, Joyce Meredith, Texas Health and Human Services Commisson, Carolyn Reese, MSN, R.N., Blinn College, Brenda Renfro‐King, R.N., McLennan Community College, Jacqueline Smith, Texas Health and Human Services Commisson, Camden Frost, Texas Health and Human Services Commisson, Sean Steele, Texas Department on Aging and Disability Services, Sunny Stout, R.N., Senior Care Centers, Mavon Tidwell, R.N., Marble Falls High School, Kingsland Hills Care Center, Anne Trejo, Texas Health and Human Services Commisson. © 2016 Texas Health and Human Services Commisson (formerly Texas Department of Human Services) TEXAS HEALTH AND HUMAN SERVICES COMMISSION (HHSC) 1 TEXAS MEDICATION AIDE AND BASIC COURSE CURRICULUM 100‐hour curriculum Table of Contents: Medication Aide and basic course curriculum Unit I.
    [Show full text]
  • Tamás F. Freund
    BK-SFN-NEUROSCIENCE_V11-200147-Freund.indd 50 6/19/20 2:08 PM Tamás F. Freund BORN: Zirc, Hungary June 14, 1959 EDUCATION: Loránd Eötvös University, Budapest, Hungary, Biologist (1983) Semmelweis University, Budapest and Hungarian Academy of Sciences, PhD (1986) APPOINTMENTS: Postdoctoral Fellow, Anatomy, Semmelweis University–Hungarian Academy of Sciences (1986–1990) Visiting Research Fellow, MRC Unit, Pharmacology, Oxford University (1986–1988) Head of Department, Institute of Experimental Medicine, Hungarian Academy of Sciences (IEM-HAS), Budapest (1990–1994) Professor, IEM-HAS, Deputy Director (1994–2002) and Director (2002–present) Professor and Head of Department, Péter Pázmány Catholic University, Budapest (2000–present) HONORS AND AWARDS (SELECTED): Drs. C. and F. Demuth Swiss Medical Research Foundation Award, Switzerland (1991) KRIEG Cortical Kudos Cortical Explorer Award of the Cajal Club (1991, USA) KRIEG Cortical Kudos Cortical Discoverer Award and the Cajal Medal (1998, USA) Dargut and Milena Kemali Foundation Award, FENS Forum, Berlin (1998) Fellow, Hungarian Academy of Sciences (1998), Vice President (since 2014) Bolyai Prize (2000), Széchenyi Prize, (2005), Prima Primissima Award (2013, Hungary) Fellow, Academia Europaea (2000, London) and Academia Scientiarum et Artium Europaea (2001) Fellow, German Academy of Sciences Leopoldina (2001) President, Federation of European Neuroscience Societies (FENS, 2004–2006) The Brain Prize (2011, Grete Lundbeck Foundation, Denmark) Fellow, American Academy of Arts and Sciences (2014) Doctor Honoris Causa, University of Southern Finland (2015) Tamás Freund’s main achievements include the discovery of new molecular pathways in nerve cell communication, identity and principles of neuron connectivity fundamental to cortical circuitry, and the generation of network activity patterns underlying multiple stages of information processing and storage in the brain.
    [Show full text]
  • Crystalline Obstruction of the Male Feline Urethra John J
    Volume 29 | Issue 3 Article 2 1967 Crystalline Obstruction of the male Feline Urethra John J. Andrews Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/iowastate_veterinarian Part of the Small or Companion Animal Medicine Commons, and the Veterinary Physiology Commons Recommended Citation Andrews, John J. (1967) "Crystalline Obstruction of the male Feline Urethra," Iowa State University Veterinarian: Vol. 29 : Iss. 3 , Article 2. Available at: https://lib.dr.iastate.edu/iowastate_veterinarian/vol29/iss3/2 This Article is brought to you for free and open access by the Journals at Iowa State University Digital Repository. It has been accepted for inclusion in Iowa State University Veterinarian by an authorized editor of Iowa State University Digital Repository. For more information, please contact [email protected]. Crystalline Obstruction of the Male Feline Urethra by John J. Andrews Obstructive urolithiasis, or more cor­ cent experiments have not supported this rectly phosphocrystalluria (since calculi claim. Likewise, hypovitaminosis A has rarely occur in the feline kidney or ureter), not been supported as a cause by research occurs quite often in the male domestic experiments. cat. The female cat seems to escape this The material which forms the urethral problem because her urethra is wider and obstruction in nearly all the cases of fe­ more expansible. The male cat, however, line urolithiasis is "struvite" crystal con­ has a relatively narrow penile urethra and glomerations. Struvite (NH4MgPO,,-6H20 fine urinary crystals may obstruct and -ammonium magnesium phosphate hex­ pack this urethral canal. If this condition ahydrate) is found in three forms in the is left untreated death is the usual result.
    [Show full text]
  • Diverse Small Molecules Prevent Macrophage Lysis During Pyroptosis Wendy P
    Loomis et al. Cell Death and Disease (2019) 10:326 https://doi.org/10.1038/s41419-019-1559-4 Cell Death & Disease ARTICLE Open Access Diverse small molecules prevent macrophage lysis during pyroptosis Wendy P. Loomis1, Andreas B. den Hartigh1,BradT.Cookson1,2 and Susan L. Fink 1 Abstract Pyroptosis is a programmed process of proinflammatory cell death mediated by caspase-1-related proteases that cleave the pore-forming protein, gasdermin D, causing cell lysis and release of inflammatory intracellular contents. The amino acid glycine prevents pyroptotic lysis via unknown mechanisms, without affecting caspase-1 activation or pore formation. Pyroptosis plays a critical role in diverse inflammatory diseases, including sepsis. Septic lethality is prevented by glycine treatment, suggesting that glycine-mediated cytoprotection may provide therapeutic benefit. In this study, we systematically examined a panel of small molecules, structurally related to glycine, for their ability to prevent pyroptotic lysis. We found a requirement for the carboxyl group, and limited tolerance for larger amino groups and substitution of the hydrogen R group. Glycine is an agonist for the neuronal glycine receptor, which acts as a ligand- gated chloride channel. The array of cytoprotective small molecules we identified resembles that of known glycine receptor modulators. However, using genetically deficient Glrb mutant macrophages, we found that the glycine receptor is not required for pyroptotic cytoprotection. Furthermore, protection against pyroptotic lysis is independent of extracellular chloride conductance, arguing against an effect mediated by ligand-gated chloride channels. Finally, we conducted a small-scale, hypothesis-driven small-molecule screen and identified unexpected ion channel modulators that prevent pyroptotic lysis with increased potency compared to glycine.
    [Show full text]